Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia

Neurology

Volumn 83, Issue 6, 2014, Pages 502-509

  Irwin, David J ^a,b   McMillan, Corey T ^a,b   Suh, Eunran ^b   Powers, John ^a   Rascovsky, Katya ^a   Wood, Elisabeth M ^a,b   Toledo, Jon B ^b   Arnold, Steven E ^b,c   Lee, Virginia M Y ^b   Van Deerlin, Vivianna M ^b   Trojanowski, John Q ^b   Grossman, Murray ^a,b  

^a Penn Frontotemporal Degeneration Center Department of Neurology   (United States)

^b Institute on Aging   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FRONTOTEMPORAL DEMENTIA; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; MYELIN PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84905822004     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000668     Document Type: Article

References (40)

1. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
2. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006;59:952-962.
3. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1-4.
4. Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2012;9:189-198.
5. Rascovsky K, Hodges GM, Knopman D, et al. Determinants of survival in autopsy-confirmed patients with behavioral variant frontotemporal dementia (bvFTD): second report of the international bvFTD criteria consortium (FTDC). Alzheimers Dement 2011;7:S761-S762.
6. Hu WT, Parisi JE, Knopman DS, et al. Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia. Alzheimer Dis Assoc Disord 2007;21:S39-S43.
7. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996-2005.
8. Chiu WZ, Kaat LD, Seelaar H, et al. Survival in progressive supranuclear palsy and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2010;81:441-445.
9. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 2003;61: 349-354.
10. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011;43:699-705.
11. McMillan C, Toledo JB, Avants B, et al. Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol Aging 2014;35:1473-1482.
12. Irwin DJ, McMillan CT, Toledo JB, et al. Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 2012;69:1018-1025.
13. Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012;124:23-35.
14. Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci 2013;5:6.
15. Toledo JB, Van Deerlin VM, Lee EB, et al. A platform for discovery: the University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement Epub 2013 Aug 23.
16. Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 2011;68:581-586.
17. Wood EM, Falcone D, Suh E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol 2013;70:1411-1417.
18. Van Deerlin VM, Gill LH, Farmer JM, Trojanowski JQ, Lee VM. Familial frontotemporal dementia: from gene discovery to clinical molecular diagnostics. Clin Chem 2003;49:1717-1725.
19. Brettschneider J, Van Deerlin VM, Robinson JL, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 2012;123:825-839.
20. Yu CE, Bird TD, Bekris LM, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 2010;67: 161-170.
21. Grossman M, Peelle JE, Smith EE, et al. Category-specific semantic memory: converging evidence from bold fMRI and Alzheimer's disease. Neuroimage 2013;68:263-274.
22. Whitwell JL, Jack CR Jr, Parisi JE, et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci 2011;45:372-378.
23. Xie SX, Forman MS, Farmer J, et al. Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2008; 79:126-129.
24. Josephs KA, Knopman DS, Whitwell JL, et al. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology 2005;65: 645-647.
25. Montague P, McCallion AS, Davies RW, Griffiths IR. Myelin-associated oligodendrocytic basic protein: a family of abundant CNS myelin proteins in search of a function. Dev Neurosci 2006;28:479-487.
26. Forman MS, Zhukareva V, Bergeron C, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 2002;160:2045-2053.
27. Zhukareva V, Mann D, Pickering-Brown S, et al. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 2002;51:730-739.
28. Zhukareva V, Joyce S, Schuck T, et al. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Ann Neurol 2006;60:335-345.
29. Irwin DJ, Cohen TJ, Grossman M, et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 2012;135:807-818.
30. Brettschneider J, Del Tredici K, Irwin DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014;127:423-439.
31. Neumann M, Kwong LK, Truax AC, et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 2007;66:177-183.
32. McMillan CT, Irwin DJ, Avants BB, et al. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2013;84:949-955.
33. Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132-140.
34. Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006;129:3051-3065.
35. Whitwell JL, Josephs KA, Rossor MN, et al. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol 2005;62:1402-1408.
36. McMillan CT, Brun C, Siddiqui S, et al. White matter imaging contributes to the multimodal diagnosis of frontotemporal lobar degeneration. Neurology 2012;78: 1761-1768.
37. Borroni B, Yancopoulou D, Tsutsui M, et al. Association between tau H2 haplotype and age at onset in frontotemporal dementia. Arch Neurol 2005;62:1419-1422.
38. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-715.
39. Di Maria E, Tabaton M, Vigo T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000; 47:374-377.
40. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79: 1094-1108.